SEC Form 4 · accession 0001104659-16-089212
STEMLINE THERAPEUTICS INC · STML
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Hoberman
Officer — Chief Operating Officer
Period of report
Jan 7, 2016
Accepted (ET)
Jan 11, 2016 · 8:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001264587
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 7, 2016 | A | 150,000 | $0.00 | A | 212,562 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F2 | $5.77 | Jan 7, 2016 | A | 150,000 | A | Jan 7, 2017 | Jan 7, 2026 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F175,000 of the restricted shares will vest in three installments as follows: 25,000 shares on January 7, 2017, 25,000 shares on January 7, 2018, and 25,000 shares on January 7, 2019. 75,000 additional shares of restricted stock will vest after 4 years subject to shares vesting earlier upon the achievement of certain corporate milestones.
- F275,000 of the stock options will vest in three installments as follows: 25,000 shares on January 7, 2017, 25,000 shares on January 7, 2018, and 25,000 shares on January 7, 2019. 75,000 additional stock options will vest after 4 years subject to stock options vesting earlier upon the achievement of certain corporate milestones.